Oxford Biomedica
Oxford Biomedica, a leading gene and cell therapy company, is headquartered in the United Kingdom. Founded in 1995, the company has established itself as a pioneer in the biopharmaceutical industry, focusing on the development and manufacturing of advanced therapies for serious diseases. With a strong operational presence in Europe and North America, Oxford Biomedica is renowned for its innovative LentiVector® platform, which enables the delivery of genetic material into cells, offering unique solutions for gene therapy. The company has achieved significant milestones, including collaborations with major pharmaceutical firms and successful clinical trials that underscore its market position. Oxford Biomedica's commitment to quality and innovation has positioned it as a key player in the rapidly evolving field of gene therapy, making substantial contributions to the treatment of conditions such as cancer and rare genetic disorders.
DitchCarbon Score
How does Oxford Biomedica's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Oxford Biomedica's score of 24 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Oxford Biomedica's reported carbon emissions
In 2023, Oxford Biomedica reported total carbon emissions of approximately 3,607,700 kg CO2e. This figure includes 828,360 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 1,236,500 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity. Additionally, Scope 3 emissions amounted to about 1,542,840 kg CO2e, which includes emissions from business travel, employee commuting, and other indirect sources. Comparatively, in 2022, the company recorded total emissions of approximately 3,828,030 kg CO2e, indicating a reduction in emissions year-on-year. The breakdown for 2022 included 885,650 kg CO2e from Scope 1, 1,796,000 kg CO2e from Scope 2, and 1,767,780 kg CO2e from Scope 3. Oxford Biomedica has committed to achieving net-zero emissions across all scopes by 2050, as part of its long-term climate strategy. This commitment aligns with the Science Based Targets initiative (SBTi), which underscores the company's dedication to reducing its carbon footprint and addressing climate change effectively. The company is actively working towards these targets, with a focus on sustainable practices within the pharmaceutical and biotechnology sectors.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 1,189,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 2 | 719,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 1,400,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Oxford Biomedica is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
